Medpace (NASDAQ:MEDP) Beats Expectations in Strong Q1 But Stock Drops
Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q1 CY2025, with sales up 9.3% year on year to $558.6 million. The company’s full-year revenue guidance of $2.19 billion at the midpoint came in 1.9% above analysts’ estimates. Its GAAP profit of $3.67 per share was 20.8% above analysts’ consensus estimates.